Cencora (COR)
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
$330.95-1.86%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DistributionSnapshot 2026-09-04
QuarterlyIQ Insights · COR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 13.7% |
| Our one-year growth estimate | diamond | 5.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 7.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 4 industry peers · Company calendar date is not available
COR — credit agreement
Dated 2026-08-05
Entry into a Material Definitive Agreement. Amendment and Restatement of Multi-Currency Revolving Credit Facility On July 31, 2026, Cencora, Inc. (the “Company”) and its subsidiary Innomar Strategies Inc. entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) to further amend and restate the Amended and Restated Credit Agreement, dated as of June 4, 2025 and as amended on January 12, 2026, among the Company, the borrowing subsidiaries party thereto…
Why it matters: Completing this acquisition is key to enhancing Cencora's healthcare solutions. It could drive future growth.
Supportive ifThe acquisition will be done and part of Cencora by the end of Q3 2026.
Worry ifThe acquisition has delays or problems that push the finish date past Q3 2026.
Why it matters: High growth in this segment is key for the company's overall performance.
Supportive ifU.S. Healthcare Solutions revenue growth exceeds 5% year-over-year.
Worry ifGrowth in U.S. Healthcare Solutions segment falls below 4% year-over-year.
Why it matters: More share buybacks can show strong cash flow and management confidence.
Supportive ifCencora plans share buybacks over $1 billion in the next quarter.
Worry ifNo new share buybacks are announced. This may show cash flow problems.
Why it matters: Changes in EPS guidance show how confident management is about earnings growth. This affects investors.
Supportive ifCencora raises its adjusted diluted EPS guidance. It is now above $17.65 to $17.90.
Worry ifGuidance stays the same or goes down, showing possible challenges in reaching earnings goals.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$127 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $247 loss on $10,000 · 2.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,245 loss on $10,000 · 32.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: More share repurchases show strong cash flow and a commitment to shareholders.
Supportive ifThey announced share buybacks of over $1 billion.
Worry ifNo new share repurchases announced or plans to reduce them.
Why it matters: The new CFO's plans may affect Cencora's money performance and how well it runs.
Watch forStrong financial results or new plans are coming from CFO Eva Boratto.
Also watch forBad financial results or no clear plans after the CFO change.
Why it matters: The new CFO's plans may change future financial guidance and how investors feel.
Watch forThe new CFO gives updated financial plans that investors find good.
Also watch forThe new CFO's plans cause negative changes in financial guidance.
Why it matters: An increase in guidance shows better profits. This can help stock performance.
Supportive ifOperating income guidance raised above the current range of 11.5% to 13.5%.
Worry ifOperating income guidance stays the same or goes down.
Why it matters: A further increase in EPS guidance would signal strong ongoing performance and growth confidence.
Supportive ifAdjusted diluted EPS guidance is now above $17.95 for fiscal 2026.
Worry ifGuidance remains at or below $17.95 without further increases.